Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing the Potential Risk of Heart Failure (English, HTML)
Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing the Potential Risk of Heart Failure: English HTML file. From Health Canada, updated May 2024. View metadata, licence and the direct download on CanQuery.
- Format
- HTML
- Access
- Original download only
- Publisher-reported update
- 2024-05-08
A safety review was carried out by Health Canada to evaluate the increased risk of heart failure with the use of DPP-4 inhibitors as a follow-up to a risk communication released by the U.S. FDA stating that saxagliptin and alogliptin might increase the risk of heart failure, in particular in patients who have other risk factors for heart failure. The product safety information in the U.S. and Canada were recently updated to include this risk.
Data overview
- Formats
- HTML
- File languages
- English
- Available actions
- Access original file